camilia perorální roztok v jednodávkovém obalu - otsingu tulemused

Euroopa Liit - eesti - EMA (European Medicines Agency)

bylvay

albireo - odevixibat - cholestasis, intrahepatic - vere ja maksa ravi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - hüperkolesteroleemia - lipiidi modifitseerivad ained - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Euroopa Liit - eesti - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipiidi modifitseerivad ained - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.